Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Update

Prelude Therapeutics Incorporated (NASDAQ:PRLD) saw a large growth in short interest in January. As of January 30th, there was short interest totaling 2,074,354 shares, a growth of 23.7% from the January 15th total of 1,677,134 shares. Currently, 9.1% of the shares of the company are sold short. Based on an average daily volume of 433,527 shares, the short-interest ratio is currently 4.8 days. Based on an average daily volume of 433,527 shares, the short-interest ratio is currently 4.8 days. Currently, 9.1% of the shares of the company are sold short.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd boosted its holdings in shares of Prelude Therapeutics by 72.4% during the second quarter. XTX Topco Ltd now owns 42,573 shares of the company’s stock worth $34,000 after purchasing an additional 17,873 shares during the last quarter. AQR Capital Management LLC raised its stake in Prelude Therapeutics by 170.7% during the first quarter. AQR Capital Management LLC now owns 33,823 shares of the company’s stock worth $26,000 after purchasing an additional 21,330 shares during the period. Shay Capital LLC grew its stake in shares of Prelude Therapeutics by 33.3% during the 3rd quarter. Shay Capital LLC now owns 100,000 shares of the company’s stock valued at $144,000 after buying an additional 25,000 shares during the period. State Street Corp raised its position in shares of Prelude Therapeutics by 30.4% in the 4th quarter. State Street Corp now owns 127,292 shares of the company’s stock worth $369,000 after buying an additional 29,700 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in Prelude Therapeutics by 48.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 117,477 shares of the company’s stock valued at $341,000 after acquiring an additional 38,150 shares during the period. Institutional investors and hedge funds own 79.72% of the company’s stock.

Prelude Therapeutics Trading Up 1.9%

Shares of NASDAQ PRLD opened at $2.15 on Thursday. The stock has a market cap of $135.17 million, a PE ratio of -1.46 and a beta of 0.88. Prelude Therapeutics has a 12-month low of $0.61 and a 12-month high of $4.22. The company has a 50-day moving average of $2.21 and a 200 day moving average of $1.64.

Wall Street Analysts Forecast Growth

PRLD has been the topic of a number of recent research reports. Wall Street Zen lowered Prelude Therapeutics from a “buy” rating to a “hold” rating in a research report on Sunday, January 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prelude Therapeutics in a report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Prelude Therapeutics presently has an average rating of “Hold” and an average price target of $4.00.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated is a clinical-stage precision medicine company focused on the discovery and development of small molecule therapies for genetically defined oncology targets. By leveraging a chemical biology approach, the company aims to deliver targeted treatments that address key drivers of cancer cell growth and survival. Prelude’s pipeline emphasizes novel inhibitors designed to engage molecular pathways validated by both preclinical and clinical evidence.

Among Prelude’s lead programs is PRT2527, a selective PI3K‐alpha/delta inhibitor in Phase 1 clinical trials for solid tumors harboring PIK3CA and other pathway mutations.